miR-133-mediated regulation of the Hedgehog pathway orchestrates embryo myogenesis by Mok, Gi Fay et al.
© 2018. Published by The Company of Biologists Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction 
in any medium provided that the original work is properly attributed. 
miR-133 mediated regulation of the Hedgehog pathway orchestrates embryo myogenesis  
 
Gi Fay Mok1, Estefania Lozano-Velasco1,$, Eirini Maniou1,$, Camille Viaut1,3,$, Simon Moxon2,4, Grant 
Wheeler1 and Andrea Münsterberg1, * 
1 School of Biological Sciences, Cell and Developmental Biology, University of East Anglia, Norwich 
Research Park, Norwich, NR4 7TJ, UK 
2 The Earlham Institute, Norwich Research Park Innovation Centre, Colney Lane, Norwich NR4 7UH, 
UK 
 
3 Present address: INSERM U1016, CNRS UMR8104, Institut Cochin, Université Paris 
Descartes, Department of Development, Reproduction and Cancer, 24 Rue du Faubourg St 
Jacques, Paris 75014, France 
 
4 Present address: School of Biological Sciences, University of East Anglia, Norwich Research Park, 
Norwich, NR4 7TJ, UK 
 
$ These authors contributed equally and are listed alphabetically 
 
*Corresponding author:  
Email: a.munsterberg@uea.ac.uk 
Phone:  +441603592232 
 
 
  
  
D
ev
el
o
pm
en
t •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
http://dev.biologists.org/lookup/doi/10.1242/dev.159657Access the most recent version at 
First posted online on 25 May 2018 as 10.1242/dev.159657
 ABSTRACT 
Skeletal myogenesis serves as a paradigm to investigate the molecular mechanisms underlying 
exquisitely regulated cell fate decisions in developing embryos. The evolutionary conserved miR-133 
family of microRNAs is expressed in the myogenic lineage, but how it acts remains incompletely 
understood. Here we performed genome-wide differential transcriptomics of miR-133 knock-down 
(KD) embryonic somites, the source of vertebrate skeletal muscle. This revealed extensive 
downregulation of Sonic hedgehog (Shh) pathway components: patched receptors, Hedgehog 
interacting protein, and the transcriptional activator, Gli1. By contrast Gli3, a transcriptional repressor, 
was de-repressed and confirmed as a direct miR-133 target. Phenotypically, miR-133 KD impaired 
myotome formation and growth by disrupting proliferation, extracellular matrix deposition and 
epithelialization. Together this suggests that miR-133 mediated Gli3 silencing is critical for embryonic 
myogenesis. Consistent with this idea we found that activation of Shh signalling by either 
purmorphamine, or KD of Gli3 by antisense morpholino (MO) rescued the miR-133 KD phenotype. 
We identify a novel Shh/MRF/miR-133/Gli3 axis that connects epithelial morphogenesis with 
myogenic fate specification. 
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 INTRODUCTION 
Skeletal muscle is important for mobility and survival. Its development is a highly regulated 
process, involving developmental signals and their effector pathways, a hierarchy of transcription 
factors – the myogenic regulatory factors (MRFs) and post-transcriptional regulation by non-coding 
RNAs (Buckingham and Rigby, 2014; Mok and Sweetman, 2011).  
In vertebrate embryos, skeletal muscles of the trunk and limbs are derived from somites, transient 
paired segments that form in a regular sequence on either side of the neural tube and notochord 
(Christ and Scaal, 2008). In response to signals, including Wnt, Shh and Notch (Abou-Elhamd et al., 
2015; Abu-Elmagd et al., 2010; Borycki et al., 1999; Johnson et al., 1994; Munsterberg et al., 1995; 
Rios et al., 2011; Sieiro et al., 2016), the initially epithelial somite undergoes morphogenetic changes 
and differentiates. On the ventral side, cells dissociate to form the sclerotome, whilst the 
dermomyotome on the dorsal side remains epithelial and contributes myocyte progenitors to the 
myotome. Myotome formation initiates at the epaxial lip of the dermomyotome, abutting the neural 
tube (Gros et al., 2004). Interactions with migrating neural crest cells triggers translocation of 
dermomyotomal lip progenitors into the myotome, where they orientate, elongate and begin to 
differentiate into myocytes (Rios et al., 2011; Sieiro et al., 2016).  
Shh, derived from the notochord and floor plate, activates myogenesis (Munsterberg et al., 1995), 
and is essential for the activation of the myogenic determination gene, Myf5, in epaxial muscle 
progenitor cells in mice (Borycki et al., 1999; Gustafsson et al., 2002), or in both epaxial and hypaxial 
domains in avian embryos (Kahane et al., 2013). Myf5 activation is mediated via Gli activator proteins, 
Gli1 and Gli2, acting on a Gli-binding site in the mouse epaxial enhancer (Gustafsson et al., 2002; 
McDermott et al., 2005; Teboul et al., 2002). In the absence of Shh, the Gli3 repressor inhibits Myf5 
transcription (McDermott et al., 2005). Furthermore, in both avian and mouse embryos, Shh signalling 
is crucial for the transition from proliferating Pax7-positive progenitors to terminally differentiating 
myocytes (Kahane et al., 2013). 
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 MicroRNAs (miRNAs or miRs) are short noncoding RNAs that bind to target sites located in 3’UTRs 
of mRNAs. This interaction leads to inhibition of translation, mRNA cleavage and transcript 
degradation via deadenylation (Bartel, 2009; Bethune et al., 2012). Through their effects on target 
gene expression, miRNAs regulate developmental timing and provide robustness to cell fate 
decisions (Ebert and Sharp, 2012; Hornstein and Shomron, 2006). The miR-1/miR-206 and miR-133 
families, comprising miR-1-1/miR-1-2/miR-206 and miR-133a/miR-133b are encoded by three loci in 
mouse and human and by four loci in chicken (Sweetman et al., 2008). One member of each family 
is produced from the same primary transcripts and they play important roles in regulating proliferation, 
differentiation and cell fate specification in developing muscle (Horak et al., 2016; Mok et al., 2017). 
In mouse and chicken embryos, miR-1/miR-133a are expressed in skeletal and cardiac muscle. In 
contrast, miR-206/miR-133b are expressed in myoblasts of somites, limb buds, and head muscles 
but not in cardiomyocytes (Darnell et al., 2006; Sweetman et al., 2008). In Xenopus and zebrafish the 
miR-1/miR-206 and miR-133 families are present in skeletal muscle but not detected in the heart 
(Ahmed et al., 2015; Mishima et al., 2009). Together with myocyte enhancer factor-2 (MEF2) the 
MRFs regulate expression of miR-1, miR-206 and miR-133, in somites (Liu et al., 2007; Sweetman 
et al., 2008) and in C2C12 myoblasts (Rao et al., 2006; Rosenberg et al., 2006). In C2C12 myoblasts 
the miR-1/miR-206 and miR-133 families regulate the balance between differentiation and 
proliferation through interactions with multiple targets (Alteri et al., 2013; Chen et al., 2006; Feng et 
al., 2013; Goljanek-Whysall et al., 2012) 
We previously used miRNA knock-down (KD) in chick somites to show that miR-1/miR-206 and 
miR-133 negatively regulate BRG1/BRM-Associated Factor 60 (BAF60) variants BAF60A and 
BAF60B. This facilitates the preferential incorporation of BAF60C into the BAF/BRG1 chromatin-
remodelling complex, required for myogenesis (Goljanek-Whysall et al., 2014). In earlier somites, 
miR-206 facilitates the complete downregulation of Pax3 in the myotome, ensuring timely transition 
of myogenic progenitor to committed myoblast (Goljanek-Whysall et al., 2011). Studies in mice 
showed that miR-133a isoforms are essential for the maintenance of skeletal muscle structure and 
myofibre identity (Liu et al., 2011), and controlling brown fat differentiation through targeting Prdm16 
(Trajkovski et al., 2012); although, deletion of the miR-206/133b cluster did not result in skeletal 
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 muscle defects (Boettger et al., 2014). In zebrafish, transcriptomic analysis revealed the importance 
of miR-1 and miR-133 for sarcomeric actin organisation (Mishima et al., 2009). However, the functions 
of miR-133 in early myogenesis remain unclear. 
Here, we characterize the mechanisms that underlie the embryonic phenotype resulting from 
antagomir-mediated miR-133 KD in avian somites. Impaired myogenesis was evident from reduced 
expression of MRFs, reduced cell proliferation and impaired growth of the dermomyotome and 
myotome, as well as reduced actin accumulation and disorganized basement membrane (BM) 
deposition. Differential transcriptomics of miR-133 KD somites identified negative effects on Shh 
pathway components, suggesting a role for miR-133 in modulating Shh signalling. Expression of the 
Gli3 transcriptional repressor was de-repressed after miR-133 KD and luciferase assays confirmed 
direct regulation via a functional target site in the Gli3 3’UTR that is complementary to the miR-133 
seed sequence. Myotome formation and epithelialization, BM deposition and myogenic differentiation 
were restored in miR-133 KD somites by concomitant activation of Shh signalling using 
purmorphamine, a synthetic agonist of the smoothened (Smo) receptor (Sinha and Chen, 2006), or 
by the concomitant morpholino-mediated knock down of Gli3 repressor. Our data identify a novel 
Shh/MRF/miR-133/Gli3 axis and show that stabilization of myogenic differentiation and growth of the 
myotome require the negative regulation of Gli3 by miR-133.  
 
RESULTS 
miR-133 is expressed in nascent myoblasts  
The spatio-temporal expression of miR-133 was determined by whole mount in situ hybridization. 
In HH-stage 14 chick embryos (Hamburger and Hamilton, 1951) miR-133 was detected in epithelial 
and in differentiating somites, as well as in the neural tube, brain and anterior notochord (Fig. S1A). 
In epithelial somites, expression was detected adjacent to the neural tube, where the first myoblasts 
emerge, and at low levels throughout. The relative expression levels of miR-133 increased as somites 
matured, and in differentiating somites miR-133 was restricted to the myotome (Fig. S1A, B), as 
previously reported for older stage embryos (Goljanek-Whysall et al., 2011; Sweetman et al., 2008) .  
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 miR-133 coordinates cell fate acquisition with somite morphogenesis 
Somites are severely affected by antagomir-mediated KD of miR-133, with epithelial morphology 
lost in the dermomyotome and myotome, and Myogenin (Mgn) expression either lost completely 
(80%) or partially (20%), indicating that by 24 hours myogenesis is compromised (Figs. 1B, 4B, 
Goljanek-Whysall et al., 2014).   
To characterize in more detail the underlying cellular and molecular mechanisms, we established 
that effects resulting from miR-133 inhibition were first detected after 9 hours. Epithelial somites of 
HH14/15 embryos injected with FITC-labelled antagomir-133 (AM133) and examined after 6, 9, 12 or 
24 hours (Fig. 1A) showed partial loss of Myf5, MyoD (Fig. S2A) and Mgn expression 9 hours after 
miR-133 KD (Fig. 1B). No phenotype was detected after 6 hours and after 12 and 24 hours 
phenotypes were more pronounced (Fig. 1B and S2B). Control injections of scrambled antagomir 
(AMscr) had no effect (Fig. S3A-D). RT-qPCR confirmed significantly reduced abundance of miR-133 
in somites after AM133 injection (Fig. 1C), also observed with Northern blots (Goljanek-Whysall et 
al., 2014). Interestingly AM133 injections of the equivalent, inter-limb level somites at later stages 
(HH20), when miR-133 is expressed in a more developed myotome, did not lead to myogenic defects 
(Fig. S2C), suggesting a critical window in younger, less mature somites where miR-133 function is 
essential. 
Pax3 and Pax7 immunostaining on cryosections revealed a reduced dermomyotome size, 
confirmed by pixel measurements using Fiji/ImageJ, in AM133 injected somites compared to the 
contralateral non-injected side (HH14/15) (Fig. 2A,B). Phosphor-histone H3 (pH3) staining showed 
fewer mitotic cells present in the dermomyotome and myotome indicating impaired cell proliferation 
after miR-133 KD (Fig. 2C). Immunostaining for caspase-3 (Cas3) showed no detectable increase of 
apoptotic cells (Fig. S2D). AMscr injections did not affect dermomyotome proliferation or size (Fig. 
S3A-C).  
Epithelial organization of the dermomyotome, assessed by actin staining, showed a reduced 
number of apico-basal orientated dermomyotomal cells. Furthermore, the dermomyotomal lip was 
poorly defined, had lost its epithelial character and less actin accumulated (Fig. 2D). In addition, 
discontinuous and disorganized laminin staining suggested that basement membrane (BM) 
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 deposition was impaired and a BM had not fully formed on the basal side of dermomyotome cells or 
beneath the myotome (Fig. 2D). The BM surrounding the neural tube remained unaffected and AMscr 
injections did not affect epithelial organisation of the dermomyotome (Fig. S3D). 
 
Inhibition of miR-133 affects Shh pathway components  
The discrete molecular and cellular changes observed after 9 hours  in the dermomyotome and 
myotome following AM133 injection culminate in severe impairment of myogenesis by 24 hours (Figs. 
1, 2, S2 and S3). Genome-wide differential transcriptomics of AM133 or AMscr injected somites was 
used to identify the pathways and cellular processes involved (Fig. 3). This was done at 9 hours to 
capture the earliest events. Hierarchical clustering confirms that AM133 injected somites were more 
similar to each other than to control somites and identified differentially expressed genes (Fig. 3B). 
Gene ontology (GO) analysis shows that genes involved in processes relating to cell division were 
significantly decreased (Fig. 3C), consistent with observations that dermomyotome size and number 
of mitotic cells were reduced after miR-133 KD. 
Amongst the top 50 significantly downregulated differentially expressed (DE) genes were myogenic 
markers, Myf5 and MyoD, and sclerotome markers, Pax1 and Pax9. Strikingly, several Shh pathway 
components were also in this group, including patched-1 (Ptch1) and patched-2 (Ptch2) receptors, 
Hedgehog interacting protein (HHIP) and the transcriptional activator Gli1 (Fig. 3B, D). Thus, we 
looked for a transcriptional repressor of Shh pathway genes amongst the genes whose relative 
expression was increased. A strong candidate was Gli3, which was amongst the top 200 de-
repressed genes and its expression was significantly increased (p=0.03) (Fig. 3D). Gli3 was therefore 
a putative direct target gene for miR-133. A miR-133 target site identified in its 3’UTR, conserved in 
human, chimp, mouse, cow and frog, was validated by luciferase reporter assays. Reporter gene 
expression was inhibited significantly after transfection of miR-133. Introducing mutations into the 8-
mer seed sequence of the target site restored reporter gene expression even in presence of miR-133 
(Fig. 3E), confirming its importance. A control microRNA had no effect. Furthermore, analysis of Gli3 
protein levels by Western blot confirmed a relative increase of the short repressor isoform (Gli3Rep) 
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 in somites, following miR-133 inhibition in vivo using AM133 injection compared to control AMscr 
injected somites (Fig. 3F).  
 
Shh pathway activation rescues miR-133 KD  
The finding that Gli3, which acts predominantly as a transcriptional repressor, is a direct target for 
miR-133 and de-repressed after miR-133 KD (Fig. 3D, F), led us to test whether pharmacological 
activation of the Shh pathway can rescue the myogenic phenotype. Knock down of miR-133 
completely inhibited myogenesis after 24 hours (Fig. 1B, Fig. 4B, Fig. S2B).  However, co-injection of 
AM133 and purmorphamine, an activator of Shh signalling, restored myogenic differentiation, as 
shown by expression of Mgn (Fig. 4B). To determine whether Gli3 de-repression was critical for the 
phenotype observed, we knocked down Gli3 expression using morpholinos (MO) and examined 
whether this could rescue the AM133 induced loss of Mgn. A FITC-labelled Gli3 translation blocking 
MO was electroporated concomitant with AM133 injection (Fig. 4C, D). Western blots of transfected 
somites showed that Gli3Rep protein was reduced by Gli3 MO compared to control MO (Fig. S3F). A 
faint band representing the full-length Gli3 activator (Gli3Act) was present in both samples, consistent 
with the finding that Gli3Act becomes rapidly degraded (Wen et al., 2010). In situ hybridization showed 
that Gli3 MO restored myogenesis in AM133 treated somites (Fig. 4D), suggesting that miR-133 
mediates its effect via negative regulation of Gli3. 
Somite organization was improved after treatment with purmorphamine or the concomitant 
transfection of Gli3 MO together with AM133, however, the somites were smaller (Fig. 4B, D).  Thus, 
we examined the rescue phenotype in more detail, after 9 hours. Pax3 and Pax7 immunostaining 
showed that, although the dermomyotome was smaller, its epithelial nature was preserved in somites 
injected with AM133 and purmorphamine (Fig. 5A-D). Fewer mitotic cells were detected by pH3 
staining, compared to contralateral somites (Fig. 5C) and this was similar to somites injected with 
AM133 alone (Fig. 2C). Actin and laminin staining showed that epithelial character and BM deposition 
was restored around the dermomyotome and myotome (Fig. 5D).   
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 Finally, AM133 co-injection with purmorphamine restored expression levels of differentially 
expressed hedgehog-pathway genes (Fig. 6A). Somites injected with AMscr, or with AM133 alone, 
or with AM133 and purmorphamine were examined using RT-qPCR. Expression of Gli1, Gli2, Ptch1, 
Smo and HHIP was decreased in somites injected with AM133, whereas expression of Gli3 increased, 
consistent with the differential transcriptomics data. Purmorphamine co-injection with AM133 led to 
recovery of Shh pathway components compared to somites injected with AM133 alone. The exception 
was Gli3 expression, which remained de-repressed. This was not unexpected given that miR-133 
function was still inhibited by antagomir-133 (Fig. 6A). The relative expression of Pax3 and Pax7 
increased, whilst Myf5 and Mgn expression decreased after antagomir-133 injection. Myf5 was also 
significantly decreased after miR-133 KD in the differential transcriptomics data (Fig. 3B). Co-injection 
of purmorphamine with AM133 restored expression of pre-myogenic markers, Pax3 and Pax7, to 
levels comparable to control somites and Myf5 and Mgn levels were also rescued (Fig. 6B). In 
addition, expression of snail1, a gene associated with epithelial mesenchymal transition (EMT), or 
gremlin1, a BMP antagonist was rescued by Shh pathway activation (Fig. 6D). However interestingly, 
genes associated with proliferation, CDC20, CDK1 and FGF8, remained repressed, consistent with 
fewer pH3 positive cells and smaller somites in presence of AM133, irrespective of the presence of 
purmorphamine. This suggests that myogenic differentiation and epithelialization are uncoupled from 
proliferation and that there is differential sensitivity of these processes for GliAct/GliRep balance. 
Furthermore, there may be additional functions of miR-133, independent of Gli3 targeting and Shh 
pathway regulation. 
 
DISCUSSION  
Despite recent progress, we still do not have a complete understanding of how myogenic 
progenitor cells, once specified, can stably execute their differentiation program. microRNAs are 
involved in fine tuning of developmental processes and we use the accessibility of chicken embryos 
to investigate the function of the miR-133 family in vivo, during embryonic myogenesis using 
antagomir-mediated inhibition, differential transcriptomics and rescue experiments.  
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 Embryonic loss-of-function of miRNAs is often difficult to investigate due to functional redundancy 
of almost identical mature miRNAs produced from multiple genetic loci, thus making reverse genetic 
approaches in mice challenging. Observations from mice with genetic deletion of miR-133a-1 and 
miR-133a-2 family members suggest a role for adult skeletal muscle homeostasis (Liu et al., 2011). 
In contrast, removal of the miR-206/133b cluster did not reveal essential functions in skeletal muscle 
differentiation or regeneration (Boettger et al., 2014). The concomitant knockout (KO) of the miR-1-
1/133a-2 and miR-1-2/133a-1 clusters, which are expressed in cardiac and skeletal muscle, led to an 
early cardiac defect (Wystub et al., 2013). However an embryonic skeletal muscle phenotype was not 
reported in any of these lines, most likely due to expression from unaffected loci. Chick embryos offer 
the opportunity to perform conditional miRNA KD experiments using antagomirs that simultaneously 
inhibit the mature form of all miR-133 family members produced (Goljanek-Whysall et al., 2014). This 
has uncovered a critical function of miR-133 in the modulation of Shh signalling through direct 
targeting of Gli3, a transcriptional repressor of the pathway and of myogenesis (McDermott et al., 
2005; Wen et al., 2010).  
Shh signals, derived from the notochord and floorplate, activate myogenesis in explants of 
presegmented mesoderm and act on myogenic progenitors in the dermomyotome and 
dermomyotome lip (Borycki et al., 1999; Borycki et al., 1998; Munsterberg et al., 1995). This induces 
expression of Myf5 via Gli activator proteins. Myf5 activates expression of miR-133 via upstream E-
boxes (Rao et al., 2006; Rosenberg et al., 2006; Sweetman et al., 2008) and we show here that miR-
133 directly targets Gli3 via a conserved site in the 3’UTR (Fig. 3E). This site is conserved and was 
shown to be functional in human Sertoli cells (Yao et al., 2016). We suggest a model whereby Gli3 
silencing by miR-133 maintains the finely tuned balance of Gli activator and repressor forms during 
myogenesis (Fig. 3F). Thus, post-transcriptional silencing of Gli3 in nascent myoblasts promotes the 
stable activation of the skeletal muscle differentiation programme in response to Gli activators, Gli1 
and Gli2 (Fig. 6E). This model is consistent with the finding that concomitant Gli3 knockdown using a 
morpholino restored myogenic differentiation after miR-133 KD (Fig. 4D). In addition, miR-133 
expression, which is initiated by Myf5 in early myoblasts, is mutually exclusive with Gli3 (Fig. S1) 
(Berti et al., 2015; Mok et al., 2015; Sweetman et al., 2008). In early somites, Gli3 transcripts are 
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 excluded from Myf-5/miR-133 expressing myoblasts and restricted to the dermomyotome, including 
the dermomyotome lip (Fig. S1C). In differentiating somites, where the myogenic programme is stably 
established, miR-133 and Gli3 remain expressed in a mutually exclusive fashion, in the myotome or 
dermomyotome respectively (Goljanek-Whysall et al., 2014; Kahane et al., 2013). In later stage 
somites, AM133 injection had no effect on myogenin expression (Fig. S2C), suggesting that miR-133 
function is essential specifically during early myogenesis. In addition, the lack of a detectable 
phenotype at later stages shows that there are no non-specific, off-target or toxic effects. 
De-repression of Gli3 transcript and protein, following miR-133 KD led to inhibition of the Shh 
pathway (Fig. 3B, D, F, Fig. 6A), including the down regulation of Gli1 activator, which is important for 
Myf5 activation (Gustafsson et al., 2002; McDermott et al., 2005). Our results imply direct and indirect 
consequences resulting from disruption of the Gli1/2 and Gli3 balance in early somites . It is likely that 
early myoblasts are directly affected, with miR-133 KD leading to loss of stable myogenesis. The 
finding that concomitant Gli3 KD, using electroporation of a Gli3 MO (Fig. 4D, Fig. S3F), rescued 
myogenic gene expression suggests that miR-133 mediated post-transciptional regulation of Gli3 is 
critical to stably establish the myogenic programme. However, myogenic differentiation also involves 
extracellular matrix production and thus dermomyotome epithelial organization may be affected 
indirectly.  
Shh signal response genes expressed in the myotome include Ptch1 and Ptch2 receptors (Pearse 
et al., 2001), the Gli1 transcriptional activator, the membrane glycoprotein HHIP (Kahane et al., 2013), 
which attenuates signalling (Chuang and McMahon, 1999; Ingham and McMahon, 2001), but also 
Fgf8 (Smith et al., 2005) and the myogenic determination gene, Myf5 (Borycki et al., 1998; McDermott 
et al., 2005). Differential transcriptomics and RT-qPCR data showed that these genes are negatively 
affected by miR-133 KD in developing somites (Figs. 3B, D and 6A, B, C). Thus, they are secondary 
targets of miR-133, but they may be directly regulated by Gli3 repressor (Fig. 3F). Using motif 
searches we found potential Gli-binding sites within 2kb upstream of transcription start sites in the 
chicken Ptch1, Ptch2, Myf5 and Fgf8 genes, consistent with Ptch1 and Myf5 being direct targets for 
Gli proteins (Cohen et al., 2015; Gustafsson et al., 2002).  
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 Other genes down-regulated after miR-133 inhibition such as cell cycle associated genes, CDK1 
and CDC20, or sclerotome genes, Pax1 and Pax9 (Fig. 3B), are likely to be indirectly affected through 
feed-back mechanisms and/or non-cell autonomous mechanisms. For example, the significant 
downregulation of FGF8 could explain effects on cell proliferation and growth as well as on sclerotome 
differentiation (Fig. 3B, Fig. 6C). In addition, BMP signals cooperate with Shh to activate somitic 
chondrogenesis (Murtaugh et al., 1999; Zeng et al., 2002). BMP signalling is likely to be inhibited after 
miR-133 KD, since Gremlin1 (Grem1), a BMP antagonist, is amongst the top 50 de-repressed genes 
(Fig. 3B). This provides a possible explanation for negative effects on Pax1 and Pax9 expression. 
Interestingly, in developing limb buds Gli3 specifies digit identities by promoting cell cycle exit and 
BMP-dependent chondrogenic differentiation via controlling Grem1 expression (Lopez-Rios et al., 
2012).  
The role of Gli2 is less clear at present. While we cannot exclude that Gli2 also contributes to the 
negative regulation of Shh pathway components, we think that this is less likely. Differential 
transcriptomics showed that Gli2 was slightly de-repressed, however, this was not significant (Fig. 
3D) and not confirmed by RT-qPCR (Fig. 5A), and the Gli2 3’UTR has no predicted miR-133 target 
site. Expression patterns of Gli transcription factors in chick somites are more consistent with the idea 
that Gli3 is the main repressor of the myogenic programme: Gli1 and Gli2 are expressed in both 
dermomyotome and myotome, however, Gli3 is excluded from the myotome (Borycki et al., 1998; 
Kahane et al., 2013).  
The effect of miR-133 KD on somite differentiation is dramatic. Expression of myogenic 
differentiation genes and epithelial organization of the dermomyotome and myotome are severely 
affected (Figs. 1, 2 and S2A, B). It has been shown that Shh is important for laminin alpha 1 synthesis 
in the myotome (Anderson et al., 2009), thus suggesting miR-133 KD and the resulting Gli3 de-
repression may lead to disrupted BM assembly due to effects on laminin activation. Co-injection with 
purmporphamine restored BM deposition, indicating that rescue of Gli1, and to some extent Gli2, 
expression restores the balance of Gli proteins sufficiently to allow laminin synthesis, even in the 
presence of elevated Gli3 levels (Figs. 4E and 5D).  
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 Shh is also required to maintain the epithelial character of the dermomyotome (Kahane et al., 
2013), which was disrupted upon miR-133 KD (Figure 2C) and rescued by purmorphamine co-
injection with AM133 (Fig. 5D). Purmorphamine-mediated rescue confirms that stabilisation of the 
myogenic differentiation programme is intimately linked with cellular organization, and both depend 
on Shh pathway activity (Fig. 5E). This is in line with the close integration of epithelial morphology 
and cell fate determination mediated by notch, GSK3 and snail1 during the initiation of myogenesis 
(Sieiro et al., 2016). On the other hand, myogenesis and epithelialization were uncoupled from 
proliferation. Proliferation was not rescued due to the continued de-repression of Gli3, which may 
affect expression of mitotic signals, such as Fgf8, and cell cycle regulators, CDC20 and CDK1 (Fig. 
6A, C). Similar observations have previously been made in the limb (Lopez-Rios et al., 2012) and the 
neural tube (Cayuso et al., 2006; Ulloa et al., 2007). Finally, it has been reported that Shh causes 
premature myogenic differentiation (Borycki et al., 1999; Kahane et al., 2001; Kahane et al., 2013), 
which could also explain why proliferation was not rescued.   
Together our data uncovers a novel Shh/MRF/miR-133/Gli3 axis whereby miR-133 and its 
modulation of the Shh signalling pathway via the direct targeting of Gli3 enables the coordination of 
epithelial morphology with stabilization of the cellular differentiation programme during early 
myogenesis.  
 
MATERIALS AND METHODS 
Somite injections 
Fertilised eggs (Henry Stewart, UK) were incubated until the desired stage of development 
(Hamburger and Hamilton, 1951). Antagomir-133 (AM133) and a scrambled sequence (AMscr), with 
final concentration of 1 M, were designed as previously described (Goljanek-Whysall et al., 2011). 
The posterior six somites of HH14/15 embryos, or the equivalent inter-limb level somites of HH20 
embryos, were injected. Embryos were harvested and processed for in situ hybridisation or 
immunohistochemistry, or injected somites were dissected and processed for RNA or protein 
extraction. Purmorphamine (Sigma) was dissolved in DMSO (2 μM) (Dessaud et al., 2007) and co-
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 injected with antagomir. Gli3 anti-sense morpholino (MO) was 3’ FITC-labelled (Gene-tools) 
(Supplemental Table S1). Gli3 MO was co-injected with AM133 into the posterior six somites of 
HH14/15 embryos, followed by electroporation using six 10 msec pulses of 60 V.  
 
In situ hybridisation, immunohistochemistry and image analysis 
Whole mount in situ hybridisation (WISH) using Digoxigenin-labelled LNA oligo probe for miR-133a 
(Exiqon) or antisense RNA probes for Pax3, Myf5, MyoD, Mgn, Gli3 (a gift from Matt Towers, 
University of Sheffield) was carried out as before (Goljanek-Whysall et al., 2011). Antagomirs were 
detected using anti-FITC antibody coupled to alkaline phosphatase (Roche) as previously described 
(Goljanek-Whysall et al., 2011). Cryosections (15 μm) of 4% PFA-fixed OCT embedded embryos 
were immunostained. Primary antibodies: Pax3 (1:200), Pax7 (1:200), Laminin (1:100) from the 
Developmental Studies Hybridoma Bank (University of Iowa), and anti-rabbit phosphor-histone H3 
(1mg/ml, Merck). Phalloidin (Invitrogen) was used at 1:100 to stain actin. Secondary antibodies: anti-
rabbit or anti-mouse Alexa Fluor 647 (Invitrogen), 1 mg/ml in 5% BSA/5% goat 
serum/PBS. DAPI (Sigma) was used at 0.1 mg/ml in PBS. Sections were visualized on an Axioscope 
with Axiovision software (Zeiss, Germany). Images were imported into Fiji/ImageJ, areas of staining 
were calculated from binary images by calculating pixel numbers from injected and non-injected sides, 
when appropriate neural tube staining was removed. A minimum of 10 sections from 3 embryos were 
analysed for each experiment. Statistical analysis used GraphPad Prism (version 6) software. Mann-
Whitney non-parametric two-tail testing was applied to determine P values.  
 
RNA extraction and RT-qPCR 
RNA and microRNA isolation from somites used RNAeasy (Qiagen) and miRCURY RNA kits 
(Exiqon) according to manufacturer’s protocols. cDNA was synthesised from 600 ng of RNA using 
Maxima First Strand cDNA synthesis kit (Thermo Scientific). For microRNAs, cDNA was synthesised 
from 10 ng using Universal cDNA synthesis kit II (Exiqon). RT-qPCR was performed on a 7500 Fast 
Real Time PCR machine (Applied Biosystems) using SYBR Green PCR Master Mix (ThermoFisher) 
according to manufacturer’s instructions. Primers for miR-133a sequence 
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 UUGGUCCCCUUCAACCAGCUGU, were designed by Exiqon. Other primers (Sigma) 
(Supplemental Table S1) were designed with Primer3 software 
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi). RT-qPCR was normalized to GAPDH for 
mRNA, or RNU-6 for miRNA based on Exiqon protocols. Three independent experiments each with 
three replicate samples were performed for each RT-qPCR. The CT (Livak and Schmittgen, 2001) 
method was used to analyse gene expression levels. Statistical analysis as previously described. 
 
RNA sequencing 
Sequencing libraries were built according to Illumina Standard Protocols (Earlham Institute, 
Norwich, UK), each sample contained pooled, injected somites from 10 embryos. Sequencing was 
performed on one lane of a flow cell on a Illumina HiSeq2500 platform. cDNA was end-paired, A-
tailed and adapter-ligated before amplification and size selection. Library QC used a gel and a 
bioanalyser. Transcript abundances for each sample were estimated with Kallisto (Bray et al., 2016) 
using Gallus gallus reference cDNA set (Galgal5) downloaded from Ensembl (Yates et al., 2016). 
Differential expression (DE) between antagomir-133 (AM133) and scrambled (AMscr) injected 
samples was calculated using DESeq (Anders and Huber, 2010) with an adjusted p-value significance 
threshold of 0.05. The data has been uploaded to the NCBI SRA, accession number PRJNA384007. 
Gene ontology (GO) term analysis was performed using the DAVID Bioinformatics Resources 6.8, 
available at https://david.ncifcrf.gov/. Statistical analysis was performed using false discovery rate 
(FDR). 
 
DNA constructs, transfections and luciferase assay 
Sensor constructs contained a chick Gli3 3′UTR fragment in a modified pGL3 vector (Promega); 
for primers see Supplemental Table S1. Mutant construct replaced the miR-133a seed site gggacca 
with the sequence gttgacaa. Chick dermal fibroblast (DF1) cells were transfected in 96-well plates 
with 200 ng luciferase reporter plasmid with miR-133 or control (50 nM, Sigma) using Lipofectamine 
2000 (Invitrogen). A Renilla luciferase plasmid was included to normalize for transfection efficiency 
and transfections used triplicate samples. The miRNA mimics were identical to mature miRNA; 
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 sequences in Supplemental Table S1. Firefly and Renilla luciferase activity was measured after 24 
hours using a multi-label counter (Promega GloMax) and relative activity was calculated for each 
sample.  
 
Primary cell culture and western blot 
Somites of wild-type embryos were dissected and cultured in DMEM, 10% FBS, 1% pen/strep 
for 4 hours before being transfected with Gli3 MO (1 mM) or control MO (1 mM) using Endoporter 
PEG (Gene-tools) and protein extracted after 48 hours. Somites from AM133 or AMscr-injected 
embryos were dissected for protein extraction. 31.5 μg of protein lysate was run on pre-cast 4-15% 
polyacrylamide gels (Bio Rad) and blotted onto PVDF membrane (Bio Rad). Primary antibody for Gli3 
(1:200, 6F5 Gli3N, Genentech, Wen et al., 2010) was applied 4oC overnight before secondary 
polyclonal goat anti-mouse HRP (1:1000, P0447, DAKO) was applied for 1 hour at room temperature. 
The blots were treated with ECL substrate kit (GE Healthcare) and imaged. Primary antibody actin 
(1:1000, ab3280, Abcam) was applied at 4oC overnight; secondary polyclonal goat anti-mouse HRP 
was applied for 1 hour at room temperature. The blots were treated with ECL substrate kit and imaged. 
Quantification of blots was done using ImageJ. 
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 Figures 
 
 
 
Fig. 1. Inhibition of miR-133 leads to a myogenic phenotype. (A) Schematic overview of the 
experimental approach. Posterior somites of HH14/15 embryos were injected with FITC-labelled 
antagomiR-133 (AM133) and the downstream analysis performed by in situ hybridization. (B) 
Embryos incubated for 6, 9, 12 and 24 hours after antagomir-133 (AM133) injection as indicated. In 
situ hybridization detects transcripts for myogenin (Mgn, purple) and FITC- antagomir is detected in 
red. After 6 hours there is no change in myogenin expression in injected somites (white asterisks, 
n=7/8). After 9 hours the most posterior somites show a loss (white arrowheads) or reduced (black 
arrowheads) myogenin expression (n=12/16). The negative effect on myogenic differentiation 
becomes more pronounced after 12 hours and 24 hours (n=8/8, n=14/14). (C) RT-qPCR for miR-133 
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 of somites, pooled from a minimum of 4 embryos, injected with AM133 compared to contralateral non-
injected somites, harvested after 6, 9, 12 or 24 hours of incubation as indicated. ***p value < 0.001; 
**p value 0.001 to 0.01; ns, not significant. 
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Fig. 2. Dermomyotome growth, epithelial organization and basement membrane deposition 
are disrupted after inhibition of miR-133. (A) Schematic overview of the experimental approach. 
Posterior somites of HH14/15 embryos were injected with FITC-labelled antagomiR-133 (AM133) and 
the downstream analysis performed by immunostaining after 9 hours incubation. (B) Immunostaining 
for Pax3, Pax7, FITC and DAPI as indicated. The areas positive for Pax3 or Pax7 staining within the 
somite were quantified using Fiji/ImageJ and were significantly smaller in AM133 injected somites 
compared to non-injected contralateral control side. Higher magnification images of injected somites 
showed disruption to dermomyotome morphology (white arrowheads). (C) Immunostaining for pH3, 
FITC and DAPI as indicated. The number of pH3-positive cells was significantly reduced in AM133 
injected somites (white arrowheads) compared to the contralateral side. ***p value < 0.001. (D) 
Immunostaining for F-actin, laminin, FITC and DAPI as indicated. Higher magnification images of 
non-injected and injected somites stained for F-actin or laminin. White arrowheads indicate 
disorganized and disrupted staining in the dermomyotome region. Scale bar 50 μm.   
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Fig. 3. Differential transcriptomics reveals mis-regulation of Shh pathway components and 
identifies Gli3 as direct miR-133 target. (A) Schematic overview of the experimental approach. 
Posterior somites of HH14/15 embryos were injected with FITC-labelled antagomiR-133 (AM133) or 
scrambled-antagomir (AMscr) and harvested after 9 hours for RNA isolation and sequencing. (B) 
Heatmaps of the top 50 genes significantly downregulated or upregulated after miR-133 knock-down 
shows clustering of six samples injected with AMscr or with AM133.  (C) Gene ontology (GO) analysis 
showed that amongst the downregulated differentially expressed (DE) group, genes associated with 
cell cycle processes were significantly overrepresented. The false discovery rates (FDRs) are shown 
for these genes. (D) Table showing Hedgehog (Hh) pathway genes that were de-repressed (yellow) 
and repressed (blue) including the transcriptional regulator Gli3, with log2 fold change and p-values.  
(E) Conservation of miR-133 seed sequence pairing region within the Gli3 3’UTR of different species. 
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 Luciferase assays validate Gli3 as a direct target for miR-133. Schematic of the chick Gli3 gene with 
a predicted target site containing an 8-mer seed match (red) present in the 3’UTR. Mutations 
(underlined) introduced into the predicted target site were designed to disrupt base pairing with the 
miR-133 seed region. A modified pGL3 vector containing a 1070 bp fragment of the chick Gli3 3’UTR 
downstream of the firefly luciferase reporter gene. Transfection of reporter plasmids into DF1 cells 
either on its own (white), or with a control miR mimic (black), or with miR-133 mimic (grey) confirms 
negative regulation of the reporter. The response was rescued after mutation of the target site. ***p 
value < 0.001; ns, not significant. (F) Western blot of somites injected with AMscr or AM133 shows 
increased amount of Gli3Rep protein. Quantitative analysis was performed on three biological 
replicates. *p value < 0.1, ns, not significant. 
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Fig. 4. Pharmacological activation of Shh pathway or Gli3 knock down restores myogenesis 
in absence of miR-133 function. (A) Schematic overview of the experimental approach. Posterior 
somites of HH14/15 embryos were injected with FITC-labelled antagomiR-133 (AM133) with 
purmorphamine (purm) or FITC-labelled scrambled-antagomir (AMscr) with DMSO as control and the 
downstream analysis performed by in situ hybridization after 24 hours incubation. (B) In situ 
hybridization showed that myogenin (Mgn) expression was lost (white arrowheads) after AM133 with 
DMSO injection, n=8/8. Co-injection of AM133 with purmorphamine, a synthetic agonist of the 
smoothened receptor, rescued myogenesis (black arrowheads). Mgn was expressed and the 
epithelial nature of the dermomyotome was preserved, but myotome size was reduced, n=14/14. 
Whole mount and sections are shown. (C) Schematic overview of the experimental approach. 
Posterior somites of HH14/15 embryos were injected with FITC-labelled antagomiR-133 (AM133) with 
Gli3 morpholino (MO), electroporated and the downstream analysis performed by in situ hybridization 
after 24 hours incubation. (D) Co-transfection of AM133 with Gli3 MO rescued myogenesis (black 
arrowheads), although myotome size was reduced (n=7/10). Whole mount and sections are shown. 
Area measurements obtained using Fiji/ImageJ. ***p value < 0.001.  
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Fig. 5. Shh pathway activation in antagomir-133 injected somites restores dermomyotome 
morphology, epithelial organisation and basement membrane desposition but not 
proliferation. (A) Schematic overview of the experimental approach. Posterior somites of HH14/15 
embryos were injected with FITC-labelled antagomiR-133 (AM133) with purmorphamine (purm) and 
the downstream analysis performed by immunostaining after 9 hours incubation. (B) Immunostaining 
for Pax3 or Pax7, FITC and DAPI, and area measurements after AM133 with purmorphamine 
injections. (C) Immunostaining for pH3, FITC and DAPI, and counting of positive cells after AM133 
plus purmorphamine injections. The number of pH3-positive cells was reduced (white arrowheads) in 
AM133 with purmorphamine injected somites compared to the contralateral side. (D) Epithelial 
organization and basement membrane deposition were improved after co-injection of purmorphamine 
with AM133. Immunostaining for F-actin, laminin, FITC and DAPI as indicated. Higher magnification 
of non-injected and injected somites with the dermomyotome, dorsomedial lip, and more continuous 
BM staining beneath the myotome indicated by white arrowheads. Scale bar 50 μm. ***p value < 
0.001.  
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Fig. 6. Purmorphamine restores expression of Shh pathway and myogenic genes, however, 
Gli3 and cell cycle genes remain de-regulated in absence of miR-133 function. (A) RT-qPCR for 
Shh pathway components, (B) myogenic genes, (C) cell cycle genes and (D) a regulator of EMT and 
BMP signalling, as indicated. White columns represent somites injected with scrambled antagomir 
(AMscr), black columns represent somites injected with antagormiR-133 (AM133), grey columns 
represent somites injected with AM133 with purmorphamine. (E) Summary of regulatory interactions 
identified in this study, see text for details. NT, neural tube; FP, floor plate; NC, notochord; DM,  
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Fig. S1. Expression of miR-133 in developing somites. Whole mount in situ hybridization using 
double Digoxigenin-labelled LNA probes (Exiqon) shows restricted expression of miR-133 in the 
neural tube (NT), anterior notochord (NC) and medial somites but no expression in the sclerotome 
(SC).  (A) HH14 stage embryo, 1-4 indicates levels of cryosections shown in panels 1-4, with a 
schematic representing somite expression. (B) RT-qPCR for miR-133 shows a relative increase of 
expression in more mature, anterior somites compared to posterior epithelial somites, 8 biological 
replicates. ***p value < 0.001; **p value 0.001 to 0.01; *p value 0.01 to 0.1. Scale bar, 200 μm in panel 
A; 50 μm in panel 4. (C) Comparison of miR-133 and Gli3 expression in developing somites. Higher 
magnification of somites show miR-133 expressed in nascent myoblasts (MY) and Gli3 in the 
dermomyotome (DM).  
 2 
 
 
Fig. S2. Inhibition of miR-133 leads to a myogenic phenotype in early somites, but not in 
differentiating somites. Embryos were injected with FITC-labelled antagomir-133 (AM133) at 
HH14/15 or HH20. Whole mount in situ hybridisation was performed for Myf5, MyoD, Mgn or Pax3 as 
indicated. (A) 9 hour incubation, (B) 24 hour incubation post-injection. (C) AM133-injected into inter-
limb somites at HH20 and incubated for 24 hours. Antisense probes (purple), FITC-labelled antagomir 
(red). Number of embryos indicated on each panel. White arrowheads indicating loss of expression 
on injected side; black arrowheads indicating reduced expression or no change in expression on 
injected side. (D) Immunostaining for Cas3, an apoptosis marker, in embryos injected with AM133 at 
HH14/15 and incubated for 9 hours show no difference in AM133 injected side compared to 
contralateral non-injected side. Scale bar 50 μm. 
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Fig. S3. Dermomyotome growth, epithelial organization and basement membrane deposition 
are not affected by injection of a scrambled antagomir. (A) Schematic representation of the 
experimental procedure. Somites of HH14/15 embryos were injected with FITC-labelled scrambled 
antagomir (AMscr) and processed for immunostaining after 9 hours. (B) Somites were cryosectioned 
and immunostained for Pax3, Pax7, FITC and DAPI as indicated. The areas positive for Pax3 or Pax7 
staining within the somite were quantified using Fiji/ImageJ. There was no significant difference 
between injected and non-injected contralateral control side. (C) Immunostaining for pH3, FITC and 
DAPI as indicated. The number of pH3-positive cells was similar in AMscr injected somites compared 
to the contralateral side. Scale bar 50 μm; ns, not significant. (D) Immunostaining for F-actin, laminin, 
FITC and DAPI as indicated. Epithelial organization and basement membrane deposition were not 
affected and were similar on both sides. Scale bar 50 μm; ns, not significant. (E) Western blot 
detecting Gli3 protein in somites injected with AMscr or AM133 shows increased level of Gli3Rep 
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protein after miR-133 KD. (F) Western blot detecting Gli3 protein in primary cultured somites 
transfected with control MO or Gli3 MO shows reduced Gli3 protein after Gli3 MO.  
 
 
 
 
 
 
Fig. S4: Differential transcriptomics of somites after miR-133 KD. (A) Gene Ontology (GO) 
terms of genes expressed at higher levels in AM133 injected somites were associated with 
angiogenesis and tube morphogenesis. (B) However, the false discovery rates (FDRs) for these 
were significantly higher compared to GO terms associated with the downregulated DE genes. 
 
 
 
 
Fig. S5. Purmorphamine mediated activation of the Shh pathway rescues myogenic 
differentiation in absence of miR-133 function. Co-injection of FITC-labelled antagomir-133 
(AM133) and purmorphamine (purm) into HH14/15 embryos was examined by in situ hybridisation for 
myogenin (Mgn) transcripts, which indicates normal expression after 9 hours incubation (n=6/6). Mgn 
antisense probe (purple), FITC-labelled antagomir (red). 
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Table S1 – PCR and mutagenesis primers, mimics and siRNA  
cGli1 RT F ACCTCTCCATCAGCACCATC 
cGli1 RT R TTGGCTGTCAGAGGGCTACT 
cGli2 RT F CACCATCAGCTCTGCCTACA 
cGli2 RT R TGAGCTGGTGTGAGGTTCAG 
cGli3 RT F CTCACCTCTTTCCAGCGTTC 
cGli3 RT R AATGTACGGGTGAGGAGTGC 
cPtch1 RT F GTGGAAGTTGGTGGACGAGT 
cPtch1 RT R CATGTACTCTGCTGGCCTGA 
cPtch2 RT F GAGTGAGGAGAAGGCAGGTG 
cPtch2 RT R CATGGTGACACAGGCATAGG 
cSmo RT F GACAACCCCAAGAGCTGGTA 
cSmo RT R CACAAAGAAGCAGGCATTGA 
cHHIP RT F CCCTCGACGATATGGAAGAA 
cHHIP RT R GTGGTGATCCACAGCACATC 
cPax3 RT F AGCAGAGCAACTGGAAGAGC 
cPax3 RT R GGTGGTTGAAAGCCATCAGT 
cPax7 RT F GCATCAAATTCGGGAAGAAA 
cPax7 RT R CTCTTCAAAGGCAGGTCTGG 
cMyf5 RT F CAACCCCAACCAGAGACTCC 
cMyf5 RT R GAGTCCGCCATCACATCGGA 
cMgn RT F GGCTTTGGAGGAGAAGGACT 
cMgn RT R CAGAGTGCTGCGTTTCAGAG 
cCDC20 RT F CCCTCAGCTGGAACAGCTAC 
cCDC20 RT R TGGTGCTGAGTGAAGGTCTG 
cCDK1 RT F TATAAAGGGCGCCACAAAAC 
cCDK1 RT R TCTTGAGGTCCATGGAAAGG 
cFGF8 RT F AGCAGAGCCTGGTGACAGAT 
cFGF8 RT R TTTCCCCTTCTTGTTCATGC 
cSNAI1 RT F CGATGCTCAGACCAGGAAAT 
cSNAI1 RT R AAGGGCTTTTCACCAGTGTG 
cGREM1 RT F AGGCACTGCACATCACTGAG 
cGREM1 RT R TCAGGGCAGTTGAGGGTAAC 
cGAPDH RT F TCTCTGGCAAAGTCCAAGTG 
cGAPDH RT R TCACAAGTTTCCCGTTCTCAG 
cGLI3-UTR F GCAGATCT TTTCACTTTCCACAAATCTGG 
cGLI3-UTR R ATGCTAGC TCAATCTGCC CAGTGAAATT A 
cGLI3-UTR-MUT F GCCTTATTTTGTGTTATCCTTTAACAGAGAGTTGACAAGATACGTTGACAAATTTTCACAATGAGG 
cGLI3-UTR-MUT-R CCTCATTGTGAAAATTTGTCAACGTATCTTGTCAACTCTCTGTTAAAGGATAACACAAAATAAGGC 
c-miR-133a mimics 5’-UUGGUCCCCUUCAACCAGCUGU-3’   5’-AGCUGGUAAAAUGGAACCAAA U-3’ 
Sigma control siRNA MISSION siRNA Universal negative control (#1) Sigma; product number SIC001 
Gli3 MO 5’- ACGTATCTTGGTCCCTCTCTGTTAA-3’ 
Control MO Standard control from GeneTools  
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